“Manuel Asensio doesn't bet often. But when he does, it's wise to pay attention.”

Paul Kaihla. eCompany Now

Other resources of interest

A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio
 
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Click here
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
Manuel Asensio Report: Oct. 26, 1998 BioTime posters fail to generate interest or support claims.
Manuel Asensio and Asensio & Company, Inc. ("Asensio") report that the American Society of Anesthesiologists held its Annual Meeting in Orlando, Florida on October 17-21, 1998. BioTime, Inc. (OTC: BTIM) (Price: $10.625) presented two posters at this conference. A poster session titled "Comparison of Intraoperative Administration of Hextend® Versus Hespan® for the Treatment of Hypovolemia During Major Surgery" was presented in the morning on October 20th. A Poster-Discussion session was held in the afternoon on October 20th titled "The Effects of Hextend® and Hespan® on Thromboelastography." Manuel Asensio and Asensio further report that neither of these posters nor their abstracts contained any new data concerning the results of Hextend’s clinical trial. Claims that posters contained new data that support the belief that Hextend has any safety, including reduced bleeding, or any other advantage over Hespan products are entirely false. In addition, there was no mention of BioTime or Hextend in any literature or sign posted in the Abbot conference booth. There was no claim that Hextend was coming soon or that FDA approval is imminent.
 
[ Back ]
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.
© 2010 Asensioexposes!com offers accurate facts that disproves past criticism of the Manuel Asensio Reports. Web Directory
A closer look at Manuel Asensio biography, Manuel Asensio positive outcomes, Manuel Asensio Reports, Manuel Asensio Research Legacy and other related information to Manuel Asensio.